Trial of pimavanserin in dementia-related psychosis
Open accessAbstract
BACKGROUND: inverse agonist and antagonist pimavanserin on psychosis related to various causes of dementia are not clear. METHODS: We conducted a phase 3, double-blind, randomized, placebo-controlled discontinuation trial involving patients with psychosis related to Alzheimer's disease, Parkinson's disease dementia, dementia with Lewy bodies, frontotemporal dementia, or vascular dementia. Patients received open-label pimavanserin for 12 weeks. Those who had a reduction from baseline of at least 30% in the score on the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions (SAPS-H+D, with higher scores indicating greater psychosis) and a Clinical Global Impression-Improvement (CGI-I) score of 1 (very much improved) or 2 (much improved) at weeks 8 and 12 were randomly assigned in a 1:1 ratio to continue receiving pimavanserin or to receive placebo for up to 26 weeks. The primary end point, assessed in a time-to-event analysis, was a relapse of psychosis as defined by any of the following: an increase of at least 30% in the SAPS-H+D score and a CGI-I score of 6 (much worse) or 7 (very much worse), hospitalization for dementia-related psychosis, stopping of the trial regimen or withdrawal from the trial for lack of efficacy, or use of antipsychotic agents for dementia-related psychosis. RESULTS: Of the 392 patients in the open-label phase, 41 were withdrawn for administrative reasons because the trial was stopped for efficacy; of the remaining 351 patients, 217 (61.8%) had a sustained response, of whom 105 were assigned to receive pimavanserin and 112 to receive placebo. A relapse occurred in 12 of 95 patients (13%) in the pimavanserin group and in 28 of 99 (28%) in the placebo group (hazard ratio, 0.35; 95% confidence interval, 0.17 to 0.73; P = 0.005). During the double-blind phase, adverse events occurred in 43 of 105 patients (41.0%) in the pimavanserin group and in 41 of 112 (36.6%) in the placebo group. Headache, constipation, urinary tract infection, and asymptomatic QT prolongation occurred with pimavanserin. CONCLUSIONS: In a trial that was stopped early for efficacy, patients with dementia-related psychosis who had a response to pimavanserin had a lower risk of relapse with continuation of the drug than with discontinuation. Longer and larger trials are required to determine the effects of pimavanserin in dementia-related psychosis. (Funded by Acadia Pharmaceuticals; HARMONY ClinicalTrials.gov number, NCT03325556.).
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
An RCT of pimavanserin withdrawal in dementia-related psychosis was stopped early due to lower rates of relapse in treatment versus placebo, driven by effects in people with Parkinson's disease.
“An RCT of pimavanserin (an atypical antipsychotic with selective serotonin 5-HT2a inverse agonist effect) withdrawal in dementia-related psychosis was stopped early due to lower rates of relapse in the treatment versus placebo groups, which appeared to be driven by effects in people with Parkinson's disease .(538)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [538]
The Double-Blind Phase reports relapse in 13% of the pimavanserin group versus 28% of the placebo group, and says the trial was stopped after crossing its efficacy boundary. The discussion near p. 319 says patients with Parkinson’s disease may have skewed the results in favor of pimavanserin, but it does not establish that they drove the treatment effect. (LLM, conf=0.85)
Experimental — accuracy not yet measuredPimavanserin produced a delay in psychosis relapse (p < 0.05) and a lower risk of relapse with continuation of the drug in probable AD with agitation and aggression (NCT 03118947, NCT 03325556).
“Pimavanserin (Nuplazid) Inverse agonist and antagonist of 5-HT2A in neurotransmission Completed phase 2 (2017–2019) Probable AD who has symptoms of agitation and aggression (1) Promising reduction of psychosis score in AD, also see [ 74 ] and (2) delay in psychosis relapse ( p < 0.05) and a lower risk of relapse with the continuation of the drug [ 75 ] 03118947 03325556”
From Current therapeutics for Alzheimer’s disease and clinical trials (2024) · cites this paper as [74]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · see citing works
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · see citing works
(1976) · Medical Entomology and Zoology · Cited by 8,899 · see citing works
Relatives of the Impaired Elderly: Correlates of Feelings of Burden
Zarit, S. H., Reever, K. E., & Bach-Peterson, J. (1980) · The Gerontologist · doi:10.1093/geront/20.6.649 · Cited by 5,810 · see citing works
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221 · see citing works
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069 · see citing works
Self-citationSubjective and objective sleepiness in the active individual
Åkerstedt, T., & Gillberg, M. (1990) · International Journal of Neuroscience · doi:10.3109/00207459008994241 · Cited by 3,088 · see citing works
Clinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027 · see citing works
Self-citationThe Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,655 · see citing works
Scale for Assessment of Positive Symptoms (SAPS) 1984
Andreasen, N. C. (1995) · Open Scholarship Institutional Repository (Washington University in St. Louis) · Cited by 2,423 · see citing works
Cummings, J. L., Isaacson, S., Mills, R., Williams, H., Chi‐Burris, K., Corbett, A., Dhall, R., & Ballard, C. G. (2013) · The Lancet · doi:10.1016/s0140-6736(13)62106-6 · Cited by 954 · see citing works
Self-citationDiagnostic Criteria for Vascular Cognitive Disorders: A VASCOG Statement
Sachdev, P., Kalaria, R., O’Brien, J., Skoog, I., Alladi, S., Black, S. E., Blacker, D., Blazer, D. G., Chen, C., Chui, H., et al. (2014) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000034 · Cited by 852 · see citing works
Predictors of Nursing Home Placement in Parkinson's Disease: A Population‐Based, Prospective Study
Aarsland, D., Larsen, J. P., Tandberg, E., & Laake, K. (2000) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2000.tb06891.x · Cited by 811 · see citing works
Gale, S. A., Acar, D., & Daffner, K. R. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.01.022 · Cited by 702 · see citing works
Reus, V. I., Fochtmann, L. J., Eyler, A. E., Hilty, D. M., Horvitz-Lennon, M., Jibson, M. D., Lopez, O. L., Mahoney, J., Pasic, J., Tan, Z. S., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.173501 · Cited by 441 · see citing works
Manual for the Extrapyramidal Symptom Rating Scale (ESRS)
Chouinard, G., & Margolese, H. C. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.02.013 · Cited by 418 · see citing works
Peters, M. E., Schwartz, S., Han, D., Rabins, P. V., Steinberg, M., Tschanz, J. T., & Lyketsos, C. G. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14040480 · Cited by 400 · see citing works
On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis
Hacksell, U., Burstein, E. S., McFarland, K., Mills, R., & Williams, H. (2014) · Neurochemical Research · doi:10.1007/s11064-014-1293-3 · Cited by 302 · see citing works
Lyketsos, C. G., Colenda, C. C., Beck, C. M., Blank, K., Doraiswamy, M. P., Kalunian, D. A., & Yaffe, K. S. (2006) · American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000221334.65330.55 · Cited by 275 · see citing works
Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses
Tampi, R. R., Tampi, D. J., Balachandran, S., & Srinivasan, S. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622316658463 · Cited by 267 · see citing works
Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease
Devanand, D. P., Mintzer, J. E., Schultz, S. K., Andrews, H., Sultzer, D. L., de la Pena, D., Gupta, S., Colon, S., Schimming, C., Pelton, G. H., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114058 · Cited by 193 · see citing works
Self-citationBallard, C. G., Bannister, C., Khan, Z., Cummings, J. L., Demos, G., Coate, B., Youakim, J. M., Owen, R., Stankovic, S., Tomkinson, E. B., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30039-5 · Cited by 192 · see citing works
Self-citationMintzer, J. E., Tune, L. E., Breder, C. D., Swanink, R., Marcus, R. N., McQuade, R. D., & Forbes, A. (2007) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181557b47 · Cited by 157 · see citing works
Tariot, P. N., Schneider, L. S. S., Katz, I. R., Mintzer, J. E., Street, J. S., Copenhaver, M. D., & Williams-Hughes, C. (2006) · American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000196628.12010.35 · Cited by 146 · see citing works
Self-citationDeberdt, W. G., Dysken, M. W., Rappaport, S. A., Feldman, P. D., Young, C. A., Hay, D. P., Lehman, D. L., Dossenbach, M. R. K., Degenhardt, E. K., & Breier, A. F. (2005) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200508000-00012 · Cited by 129 · see citing works
Mintzer, J., Greenspan, A., Caers, I., Van Hove, I., Kushner, S., Weiner, M., Gharabawi, G., & Schneider, L. S. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000194643.63245.8c · Cited by 94 · see citing works
Brief Psychosocial Therapy for the Treatment of Agitation in Alzheimer Disease (The CALM-AD Trial)
Ballard, C. G., Brown, R. G., Fossey, J., Douglas, S., Bradley, P., Hancock, J., James, I. A., Juszczak, E., Bentham, P., Burns, A. S., et al. (2009) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181b0f8c0 · Cited by 85 · see citing works
Self-citationEspay, A. J., Guskey, M. T., Norton, J. C., Coate, B., Vizcarra, J. A., Ballard, C. G., Factor, S. A., Friedman, J. H., Lang, A. E., Larsen, N. J., et al. (2018) · Movement Disorders · doi:10.1002/mds.27488 · Cited by 55 · see citing works
Self-citationCerebral correlates of psychotic syndromes in neurodegenerative diseases
Jellinger, K. A. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01311.x · Cited by 43 · see citing works
Vernon, E. K., Cooley, B., Rozum, W., Rattinger, G. B., Behrens, S., Matyi, J., Fauth, E. B., Lyketsos, C. G., & Tschanz, J. T. (2018) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2018.11.010 · Cited by 36 · see citing works
Lornstad, M. T., Aarøen, M., Bergh, S., Benth, J. Š., & Helvik, A.-S. (2019) · BMC Geriatrics · doi:10.1186/s12877-019-1126-y · Cited by 24 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- [1]1. Gale SA, Acar D, Daffner KR. Demen- tia. Am J Med 2018; 131: 1161-9.
- [2]2. Jellinger KA. Cerebral correlates of psy- chotic syndromes in neurodegenerative dis- eases. J Cell Mol Med 2012; 16: 995-1012.
Cited by
Sorted by citations
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860 · see citing works
The neuropsychiatry of Parkinson’s disease: advances and challenges
Weintraub, D., Aarsland, D., Chaudhuri, K., Dobkin, R., Leentjens, A., Rodríguez-Violante, M., & Schrag, A. (2022) · Lancet Neurology · doi:10.1016/s1474-4422(21)00330-6 · Cited by 350 · see citing works
Self-citationTanner, C. M., & Ostrem, J. L. (2024) · New England Journal of Medicine · doi:10.1056/nejmra2401857 · Cited by 398 · see citing works
Medical, surgical, and physical treatments for Parkinson's disease.
Foltynie, T., Bruno, V., Fox, S. H., Kühn, A., Lindop, F., & Lees, A. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01429-0 · Cited by 197 · see citing works
Dementia Prevention and Treatment
Reuben, D. B., Kremen, S. A., & Maust, D. T. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.8522 · Cited by 214 · see citing works
Frontotemporal lobar degeneration
Grossman, M., Seeley, W. W., Boxer, A. L., Hillis, A. E., Knopman, D. S., Ljubenov, P. A., Miller, B., Piguet, O., Rademakers, R., Whitwell, J. L., et al. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00447-0 · Cited by 178 · see citing works
The neuropsychiatry of Parkinson's disease: advances and challenges
Weintraub, D., Aarsland, D., Chaudhuri, К. R., Dobkin, R., Leentjens, A., Rodriguez-Violante, M., & Schrag, A. E. (2022) · UCL Discovery (University College London) · Cited by 181 · see citing works
Self-citationCorrell, C. U., Solmi, M., Cortese, S., D, M. F. M., Højlund, M., KRAEMER, H. C., McIntyre, R. S., Pine, D. S., Schneider, L. S. S., & Kane, J. M. (2023) · World Psychiatry · doi:10.1002/wps.21056 · Cited by 111 · see citing works
Rogowska, M., Thornton, M., Creese, B., Velayudhan, L., Aarsland, D., Ballard, C. G., Tsamakis, K., Stewart, R. J., & Mueller, C. (2022) · Drugs & Aging · doi:10.1007/s40266-022-00992-5 · Cited by 110 · see citing works
“Pimavanserin was further shown to reduce the risk of relapse of psychotic symptoms in a discontinuation trial including patients with dementiarelated psychosis, whereby 13% of patients on pimavanserin relapsed versus 28% of those who were switched to placebo after the initial remission of symptoms [35].”
BackgroundSelf-citationTampi, R. R., & Jeste, D. V. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220508 · Cited by 103 · see citing works
“Selective” serotonin 5-HT2A receptor antagonists
Casey, A. B., Cui, M., Booth, R. G., & Canal, C. E. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115028 · Cited by 94 · see citing works
Schizophrenia: One Name, Many Different Manifestations
Faden, J., & Citrome, L. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2022.05.005 · Cited by 89 · see citing works
Parkinson disease psychosis: from phenomenology to neurobiological mechanisms
Pagonabarraga, J., Bejr-Kasem, H., Martinez-Horta, S., & Kulisevsky, J. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-023-00918-8 · Cited by 69 · see citing works
“In a phase III, double-blind, randomized, placebo-controlled discontinuation trial in patients with dementia-related psychosis (AD, PDD or DLB), pimavanserin 34 mg per day produced statistically significant improvements in psychotic symptoms 197 .”
Induction of embryogenic competence in somatic plant cells: a review
Fehér, A., Pasternak, T. P., Ötvös, K., Miskolczi, P., & Dudits, D. (2002) · Cited by 67 · see citing works
Couteur, D. G. L., Hilmer, S. N., Glasgow, N., Naganathan, V., & Cumming, R. G. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg006.pub2 · Cited by 59 · see citing works
Emotional and Neuropsychiatric Disorders Associated with Alzheimer's Disease
Heilman, K. M., & Nadeau, S. E. (2022) · Neurotherapeutics · doi:10.1007/s13311-021-01172-w · Cited by 57 · see citing works
“Pimavanserin, a 5‐HT2A receptor inverse agonist and antagonist with little affinity for dopamine receptors, might prove to be a genuine innovation [117] (see also [118]).”
BackgroundProgress in Pharmacologic Management of Neuropsychiatric Syndromes in Neurodegenerative Disorders
Cummings, J. L., Lanctôt, K. L., Grossberg, G. T., & Ballard, C. G. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.0586 · Cited by 45 · see citing works
Self-citationLyu, Y., Meng, Z., Hu, Y., Jiang, B., Yang, J., Chen, Y., Zhou, J., Li, M., & Wang, H. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1394932 · Cited by 42 · see citing works
The VTA dopaminergic system as diagnostic and therapeutical target for Alzheimer's disease
Krashia, P., Spoleti, E., & D’Amelio, M. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1039725 · Cited by 39 · see citing works
Advances in dementia with Lewy bodies
Armstrong, M. J. (2021) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211057666 · Cited by 37 · see citing works
Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
Silvestro, S., Valeri, A., & Mazzon, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042011 · Cited by 35 · see citing works
“The subsequent clinical trial HARMONY was designed in order to understand the efficacy and safety of primavanserin in the treatment of symptoms such as delusion or hallucination, common in various types of dementia [61].”
MethodTeixeira, A. L., Rocha, N. P., & Gatchel, J. (2023) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0043-1777774 · Cited by 33 · see citing works
The role of basket trials in drug development for neurodegenerative disorders
Cummings, J. L., Montes, A., Kamboj, S., & Cacho, J. R. F. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01015-6 · Cited by 31 · see citing works
“An adequate number of patients with AD and PD entered the trial to allow subgroup assessments; the small number of patients with vascular dementia, DLB, and FTD make it difficult to draw conclusions concerning these individual sub-populations [32].”
BackgroundSelf-citationParkinson’s disease therapy: what lies ahead?
Wolff, A. W., Schumacher, N. U., Pürner, D., Machetanz, G., Demleitner, A. F., Feneberg, E., Hagemeier, M., & Lingor, P. (2023) · Journal of Neural Transmission · doi:10.1007/s00702-023-02641-6 · Cited by 32 · see citing works
Statistical analyses of ordinal outcomes in randomised controlled trials: a scoping review
Selman, C. J., Lee, K. J., Ferguson, K. N., Whitehead, C. L., Manley, B. J., & Mahar, R. K. (2024) · Trials · doi:10.1186/s13063-024-08072-2 · Cited by 30 · see citing works
Current therapeutics for Alzheimer’s disease and clinical trials
Xiao, D., & Zhang, C. (2024) · Exploration of Neuroscience · doi:10.37349/en.2024.00048 · Cited by 30 · see citing works
Cao, Y., Yu, F., Lyu, Y., & Lu, X. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.1034243 · Cited by 26 · see citing works
Current Therapies and Drug Development Pipeline in Lewy Body Dementia: An Update
MacDonald, S., Shah, A. S., & Tousi, B. (2022) · Drugs & Aging · doi:10.1007/s40266-022-00939-w · Cited by 20 · see citing works
Lü, W., Liu, F., Zhang, Y., He, X., Hu, Y., Xu, H., Yang, X., Li, J., & Kuang, W. (2024) · BMJ Mental Health · doi:10.1136/bmjment-2024-301019 · Cited by 19 · see citing works
“42 It has also recently been studied in dementia-related psychosis.”
Isaacson, S., & Citrome, L. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2069240 · Cited by 19 · see citing works
Advances in the treatment and management of frontotemporal dementia
Benussi, A., & Borroni, B. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2228491 · Cited by 19 · see citing works
“Compared to older antipsychotic agents, pimavanserin is believed to have fewer side effects [110,111], however, there is ongoing discussion surrounding this claim [112].”
BackgroundResultWeintraub, D. A., & Irwin, D. J. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001151 · Cited by 18 · see citing works
Self-citationEmerging Pharmacological Approaches for Psychosis and Agitation in Alzheimer’s Disease
Imbimbo, C., Ramusino, M. C., Leone, S., Mazzacane, F., Franco, V. D., Gatti, A., Perini, G., & Costa, A. C. (2024) · CNS Drugs · doi:10.1007/s40263-024-01133-9 · Cited by 20 · see citing works
Pimavanserin for psychosis in Parkinson's disease dementia: Subgroup analysis of the HARMONY Trial
Weintraub, D. A., Espay, A. J., Sharma, V. D., Tariot, P. N., Abler, V., Pathak, S. S., & Stankovic, S. (2023) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2023.105951 · Cited by 17 · see citing works
“HARMONY was stopped early when a prespecified interim analysis met criteria for efficacy; in the entire study population, pimavanserin was associated with a significantly lower risk of psychosis relapse than placebo in the double-blind phase of the study [15].”
InfluentialSelf-citationMa, M., Yang, Y. K., Du, G., Dai, Y., Zhu, X., Wang, W., Xu, H., Zhang, J., Zheng, L., Zou, F., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114246 · Cited by 16 · see citing works
Long-term outcomes with pimavanserin for psychosis in clinical practice
Akbar, U., & Friedman, J. H. (2022) · Clinical Parkinsonism & Related Disorders · doi:10.1016/j.prdoa.2022.100143 · Cited by 16 · see citing works
“While it has been proven to be effective in clinical trials lasting 6 weeks, and, when effective, lasting up to 26 weeks [13] in people with dementia, in general, our clinical experiences, however, demonstrate less promising results.”
BackgroundTorres-Yaghi, Y., Carwin, A., Carolan, J., Nakano, S., Amjad, F., & Pagan, F. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s324145 · Cited by 14 · see citing works
“3%) patient experiencing an increase in QTc of ≥60 ms.(103) In all studies, the effect of pimavanserin on QTc interval was not associated with related adverse events.”
BackgroundMotor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis
Abler, V., Brain, C., Ballard, C. G., Berrio, A., Coate, B., & Espay, A. J. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.919778 · Cited by 14 · see citing works
“The study designs and primary results of study 020 and HARMONY have been previously published (22, 23).”
BackgroundSelf-citationSerotonin in synucleinopathies
Hsam, O., & Kohl, Z. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114367 · Cited by 14 · see citing works
Management of Psychiatric Symptoms in Dementia
Ayhan, Y., Yoseph, S. A., & Miller, B. L. (2022) · Neurologic Clinics · doi:10.1016/j.ncl.2022.05.001 · Cited by 13 · see citing works
Oguma, T., Jino, K., Nakahara, K., Asada, H., Fuchino, K., Nagatani, K., Kouki, K., Okamoto, R., Takai, N., Koda, K., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01244 · Cited by 13 · see citing works
Risks and benefits of current and novel drugs to treat agitation in Alzheimer’s disease
Herrmann, N., Wang, H. J., Song, B. X., Bawa, K. K., & Lanctôt, K. L. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2136162 · Cited by 13 · see citing works
“(NCT03325556) with patients experiencing dementia-related psychosis [33], the study presented detailed AE results worth mentioning, especially because agitation and psychosis often co-occur [20].”
BackgroundBrüge, A., Ponimaskin, E. G., & Labus, J. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100071 · Cited by 12 · see citing works
“291 In addition, a current phase 2 or 3 clinical trial is evaluating the ef fi cacy of the 5-HT2A inverse agonist ACP-204 in patients with AD affected by psychosis (NCT06159673).”
Seritan, A. L. (2023) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887231164357 · Cited by 12 · see citing works
“Responders had a lower risk of psychosis relapse if they continued pimavanserin, as opposed to stopping it.(179) The Citalopram for Agitation in Alzheimer’s Disease (CitAD) trial demonstrated a significant improvement in agitation associated with AD with citalopram up to 30 mg daily.”
InfluentialManagement of neuropsychiatric symptoms in dementia
Devanand, D. P. (2023) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001199 · Cited by 13 · see citing works
“Pimavanserin continuation was associated with significantly lower relapse compared to patients who were switched to placebo [42].”
ResultSelf-citationPsychotic Symptoms in Patients With Major Neurological Diseases
Kim, J. S., Hong, S. B., Park, K.-W., & Lee, A. T. C. (2024) · Journal of Clinical Neurology · doi:10.3988/jcn.2023.0501 · Cited by 12 · see citing works
“79,80 Various medications such as haloperidol, risperidone, quetiapine, and olanzapine are used in patients with stroke and other types of focal neurological damage.”
BackgroundNasyrova, R. F., Kidyaeva, A. V., Петрова, М. М., & Shnayder, N. A. (2024) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2024-410 · Cited by 12 · see citing works
BPSD Patterns in Patients With Severe Neuropsychiatric Disturbances: Insight From the RECAGE Study
Cognat, E., Sabia, S., Fayel, A., Lilamand, M., Handels, R. L. H., Fascendini, S., Bergh, S., Frisoni, G. B., Fabbo, A., Tsolaki, M., et al. (2023) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2023.03.014 · Cited by 12 · see citing works
Heim, B., Peball, M., Krismer, F., Djamshidian, A., & Seppi, K. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s371641 · Cited by 11 · see citing works
“An International Parkinson Disease and Movement Disorder Society (IPMDS)-commissioned task force reviewed and made recommendations for the use of psychosis rating scales used in PD.”
BackgroundMethodResultInfluentialBenmelouka, A. Y., Ouerdane, Y., Outani, O., Alnasser, Y., Alghamdi, B. S. A., Perveen, A., Ashraf, G. M., & Ebada, M. A. (2022) · Current Alzheimer Research · doi:10.2174/1567205019666220418151914 · Cited by 11 · see citing works
Psychoplastogenic DYRK1A Inhibitors with Therapeutic Effects Relevant to Alzheimer’s Disease
Warren, H. T., Saeger, H. N., Tombari, R. J., Chytil, M., Rasmussen, K., & Olson, D. E. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01696 · Cited by 10 · see citing works
Burnand, A., Rookes, T., Mahmood, F., Davies, N., Walters, K. R., Orleans‐Foli, S., Sajid, M., Vickerstaff, V., & Frost, R. (2024) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.6129 · Cited by 10 · see citing works
The evolving therapeutic landscape of dementia with Lewy bodies
Kaila, L. V., Ikeda, M., Sultana, J., Chouliaras, L., O'Brien, J. T., & Taylor, J. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00323-0 · Cited by 10 · see citing works
Torres-Yaghi, Y. A., Carwin, A., Carolan, J., Nakano, S., Amjad, F., & Pagán, F. (2021) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 10 · see citing works
Lamotte, G. J., & Singer, W. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-98817-9.00032-6 · Cited by 9 · see citing works
Behavioral and Psychological Symptoms (BPSD) in Alzheimer’s Disease (AD): Development and Treatment
Lee, H. H., Chinna‐Meyyappan, A., Feldman, O. J., Marotta, G., Survilla, K., & Lanctôt, K. L. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_566 · Cited by 9 · see citing works
Fryc, M., Kluzik, D., Czopek, A., Jończyk, J., & Zagórska, A. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110622 · Cited by 9 · see citing works
Disease modification is not all — we need symptomatic therapies for Alzheimer disease
Cummings, J. L. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00591-9 · Cited by 9 · see citing works
Self-citationPsychotic Disorders in the Elderly
Fischer, C. E., Namasivayam, A. A., Crawford-Holland, L., Hakobyan, N., Schweizer, T. A., Muñoz, D. G., & Pollock, B. G. (2022) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2022.07.001 · Cited by 9 · see citing works
Chen, L., Ji, Y., Li, A., Liu, B., Shen, K., Su, R., Ma, Z., Zhang, W., Wang, Q., Zhu, Y., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1085569 · Cited by 8 · see citing works
“Although pimavanserin tartrate has shown the strongest anticancer effect in high-throughput drug screening (Figure S1A), several adverse events such as headache, constipation, and urinary tract infection have occurred in its clinical trials for dementiarelated psychosis (27).”
BackgroundApproaches for treating neuropsychiatric symptoms in Parkinson’s disease: a narrative review
Rodríguez-Antigüedad, J., Olmedo‐Saura, G., Pagonabarraga, J., Martínez‐Horta, S., & Kulisevsky, J. (2025) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864251336903 · Cited by 8 · see citing works
“78 However, in the realm of cognitive impairment, the situation has remained largely unchanged for over 20 years, with only one drug available that has modest effects and does not halt the progression of symptoms.”
Lewy Body Dementia: An Overview of Promising Therapeutics
Skylar‐Scott, I. A., & Sha, S. J. (2023) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-023-01292-0 · Cited by 8 · see citing works
Mani, V., & Alshammeri, B. S. (2023) · Medicina · doi:10.3390/medicina60010046 · Cited by 8 · see citing works
“It is important to recognize that antipsychotic medications may provide limited short-term relief for psychosis related to dementia [6].”
BackgroundPimavanserin Treatment for Psychosis in Patients with Dementia with Lewy Bodies: A Case Series
Rothenberg, K. G., McRae, S. G., Dominguez-Colman, L., Shutes‐David, A., & Tsuang, D. W. (2023) · American Journal of Case Reports · doi:10.12659/ajcr.939806 · Cited by 7 · see citing works
“That study included 38 participants with DLB but did not provide DLB-specific findings and was stopped early due to findings of efficacy; thus, larger studies that encompass a longer trial period and include DLB-specific findings are necessary [31].”
ResultNigović, B. (2022) · Electrochimica Acta · doi:10.1016/j.electacta.2022.141700 · Cited by 7 · see citing works
Schneider, L. S. S. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220519 · Cited by 7 · see citing works
IsHak, W. W., Meyer, A., Freire, L., Totlani, J., Murphy, N., Renteria, S., Salem, M., Chang, T., Abdelsalam, R., Khan, R., et al. (2024) · PubMed Central · Cited by 6 · see citing works
Dirks, B., D, M. F. M., Atkinson, S. D., Joyce, M. A., Thase, M. E., Howell, B., Lin, T., & Stankovic, S. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4448 · Cited by 5 · see citing works
Self-citationA New Hope in Alzheimer's Disease Psychosis: Pimavanserin
Kurhan, F., & Akın, M. (2023) · Current Alzheimer Research · doi:10.2174/1567205020666230825124922 · Cited by 5 · see citing works
Darwish, M., Bugarski‐Kirola, D., Jaworowicz, D. J., Owen, J. S., Qaraghuli, F. A., Barry, A. D., & DeKarske, D. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2315 · Cited by 4 · see citing works
Namasivayam, A. A., Fischer, C. E., Abler, V., Creese, B., Gastiazoro, M. P., Hermida, A. P., Ikeda, M., Ismail, Z., Jeste, D. V., McDermid, J., et al. (2025) · International Psychogeriatrics · doi:10.1016/j.inpsyc.2025.100133 · Cited by 3 · see citing works
“This led to a phase III, 6-month relapse prevention trial for the broader indication of DRP [64].”
Self-citationWatt, J. A., Ismail, Z., Lane, N. E., Seitz, D. P., & Goodarzi, Z. (2026) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-061724-085912 · Cited by 5 · see citing works
Neuropsychiatric symptoms in behavioral variant frontotemporal dementia: a narrative review
Page, J., Pontone, G. M., & Davydow, D. S. (2025) · International Review of Psychiatry · doi:10.1080/09540261.2025.2583257 · Cited by 3 · see citing works
“For example, pimavanserin, a serotonin receptor modulator found to have efficacy for psychosis in dementia in the HARMONY trial (Tariot et al., 2021), warrants further study in patients with psychosis in bvFTD, particularly since the HARMONY trial included only ten patients with FTD.”
Case Study 3: A 58-Year-Old Woman Referred for Evaluation of Suspected Alzheimer Dementia
Maneval, J., Woods, J. K., Feany, M. Β., Miller, M. B., Silbersweig, D., Gale, S. A., Daffner, K. R., & McGinnis, S. M. (2022) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.20220113 · Cited by 3 · see citing works
Pimavanserin and dementia-related psychosis: can HARMONY prevail?
Liu, K. Y., & Howard, R. J. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00257-x · Cited by 3 · see citing works
Pimavanserin in Dementia-Related Psychosis
Friedman, J. I. (2021) · New England Journal of Medicine · doi:10.1056/nejme2109010 · Cited by 3 · see citing works
Denomme, N., Hernández, C. C., Bock, H. A., Ohana, R. F., Bakshi, S., Sherwood, A. M., McCorvy, J. D., Daley, P. F., Callaway, W. B., Hull, J. M., et al. (2024) · Molecular Pharmacology · doi:10.1124/molpharm.123.000837 · Cited by 2 · see citing works
Atewogboye, O., Taylor, J., & Harrison, J. R. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2562151 · Cited by 2 · see citing works
“Pimavanserin, a selective serotonin inverse agonist and atypical antipsychotic, approved for the treatment of Parkinson’s disease psychosis, has shown promise in managing dementia-related psychosis [53].”
Pimavanserin and dementia-related psychosis
Tariot, P. N., Ballard, C. G., Devanand, D. P., Cummings, J. L., & Sultzer, D. L. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00466-x · Cited by 2 · see citing works
Self-citationAntipsychotics in Alzheimer’s Disease: Current Status and Therapeutic Alternatives
Maziero, M. P., Rocha, N. P., & Teixeira, A. L. (2023) · Current Alzheimer Research · doi:10.2174/0115672050287534240215052417 · Cited by 2 · see citing works
Malena, K., Rao, S., & Mosler, C. (2024) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2024.300 · Cited by 2 · see citing works
Cummings, J. L., Zhong, K., Ballard, C. G., Sano, M. C., & Mintzer, J. E. (2025) · International Psychogeriatrics · doi:10.1016/j.inpsyc.2025.100107 · Cited by 2 · see citing works
“Similarly, the relapse rate for psychosis of Parkinson’s disease was greater than the relapse rate for AD in a randomized discontinuation trial of pimavanserin suggesting differing biological underpinnings of the psychosis [25].”
InfluentialSelf-citationClinical Pipelines for Alzheimer’s Disease Psychosis and Agitation
Oguma, T., & Jino, K. (2024) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c23-00416 · Cited by 1 · see citing works
The treatment of older patients with Parkinson’s disease
Djukic, M., Yoshida-Stiksrud, E., & Nau, R. (2025) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2025.0083 · Cited by 1 · see citing works
Creese, B., Cummings, J. L., Fischer, C. E., Jeste, D., Ikeda, M., Mills, K., Ismail, Z., & Ballard, C. G. (2025) · International Psychogeriatrics · doi:10.1016/j.inpsyc.2025.100094 · Cited by 1 · see citing works
“With regard to pharmacological treatment approaches, the 5HT2A inverse agonist pimavanserin is an effective treatment for Parkinson’s psychosis and Dementia-Related Psychosis, and does not have a detrimental impact on cognition or motor functioning [26– 28].”
Self-citationCubała, W. J., Berrio, A., Chi-Burris, K., Alva, G., Chrones, L., & Pathak, S. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251345162 · Cited by 1 · see citing works
Dementia with Lewy Bodies: Updates in Diagnosis and Management
Guindin-Orama, M. I., Soto-Martínez, V., van Dyck, L. I., & Wilkins, K. M. (2025) · Current Geriatrics Reports · doi:10.1007/s13670-025-00444-z · Cited by 1 · see citing works
“It is FDA-approved for the treatment of hallucinations and delusions associated with Parkinson’s Disease psychosis and has shown efficacy in treating VH in DLB [ 40].”
Kandilakis, C. L., Felemegkas, P., Papanastasiou, A. D., Sotiropoulos, I., Kane, J. P. M., Leroi, I., Toledo, J. B., & Alexopoulos, P. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-03071-2 · Cited by 1 · see citing works
“Pimavanserin, a 5-HT2A inverse agonist approved for PD psychosis, shows efficacy in DLB as well (Cummings et al. 2022; Erskine and Taylor 2025; Tariot et al. 2021; Weintraub et al. 2024).”
Nonclinical Characterization of ACP-204, a Novel Selective 5-HT2A Receptor Inverse Agonist
Burstein, E. S., Olsson, R., Skold, N., Jansen, K. E., Azar, M., Sandiego, C., Ridler, K., Rabiner, E. A., Rhodes, G., Dey, P. M., et al. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.104932 · Cited by 1 · see citing works
The utility of a composite endpoint for tracking disease progression in Lewy body dementia
Matar, E., White, S. R., Taylor, J., Thomas, A. J., Mckeith, I. G., Kane, J., Lewis, S., Surendranathan, A., & O'Brien, J. (2026) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70260 · Cited by 1 · see citing works
“Historically, interventional trials in LBD have tended to a single domain for the primary efficacy endpoint such as cognitive outcomes (Alzheimer’s Disease Assessment Scale Cognitive subscale, 27 or MMSE, 28,29 ) neuropsychiatric symptoms (e.g., NPI, NPI-4 30 , Scale for the Assessment of Positive Symptoms 31,32 ) or…”
Clinical Diagnosis and Treatment of Anxiety in Dementia With Lewy Bodies
Wadood, A., Camp, M. E., & Kelley, B. J. (2026) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2026.05.019 · Cited by 1 · see citing works
Relapse in Dementia-related Psychosis and Clinical Decisions
Soto-Martin, M., Foff, E. P., & Devanand, D. P. (2022) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000480 · Cited by 1 · see citing works
Self-citationBehavior of KCNQ Channels in Neural Plasticity and Motor Disorders
Singh, S. P., William, M., Malavia, M., & Chu, X. (2022) · Membranes · doi:10.3390/membranes12050499 · Cited by 1 · see citing works
“Within the most recent trial, a side effect of primavanserin use as a treatment for PD was QT prolongation [114].”
Background73-Year-Old Man With Altered Mental Status and Speech Difficulties
Eller, J. S., White, J. D., & Botha, H. (2023) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.09.022 · Cited by 1 · see citing works
Wojtasik-Bakalarz, K., & Siwek, M. (2023) · Pharmacotherapy in Psychiatry and Neurology · doi:10.5114/fpn.2022.124608 · Cited by 1 · see citing works
Cilia, R., Piacentini, S. H. M. J., & Cummings, J. L. (2023) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2023.105804 · Cited by 1 · see citing works
Self-citationPimavanserin Use in Lewy Body Dementia: A Case Report Demonstrating the Medication’s Efficacy
Baker, M., Song, W., & Fusick, A. J. (2023) · Cureus · doi:10.7759/cureus.46356 · Cited by 1 · see citing works
“The SAPS was chosen as the measurement tool for the efficacy of pimavanserin as it was the original screening measure used by the HARMONY trial, a phase 3 relapse-prevention study of pimavanserin in patients with dementia-related psychosis [9].”
MethodGuillen, J. C., Rojas, G. J., Demey, I., Sarasola, D., del Hierro, X. M., Persi, G. G., Aldinio, V., de Silva, N. P., Boccazzi, J. F., Seguí, J., et al. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-240018 · Cited by 1 · see citing works
“The HARMONY study [27] analyzed the efficacy of pimavanserin for psychosis in various types of dementia.”
Challenges and proposed solutions to conducting Alzheimer’s disease psychosis trials
Ballard, C. G., Tariot, P. N., Soto‐Martin, M., Pathak, S. S., & Liu, I.-Y. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1384176 · Cited by 1 · see citing works
Self-citationMajor Neurocognitive Disorder Due to Vascular Disease
Joseph, M., Cameron-Carter, H. A., & Akinyemi, E. (2024) · Springer eBooks · doi:10.1007/978-3-031-55711-8_2 · Cited by 1 · see citing works
- Authors
- Tariot, P. N., Cummings, J. L., Soto-Martin, M. E., Ballard, C., Erten-Lyons, D., Sultzer, D. L., Devanand, D. P., Weintraub, D., McEvoy, B., Youakim, J. M., Stankovic, S., & Foff, E. P.
- Affiliations
- University of Nevada, Las Vegas (US)
- From Banner Alzheimer’s Institute and University of Arizona College of Medicine, Phoenix (P.N.T.); Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada, Las Vegas, Las Vegas (J.L.C.); Gérontopôle Alzheimer Clinical and Research Center, Centre Hospitalier Universitaire de Toulouse, Geriatric Department, Maintain Functions and Intrinsic Capacities with Aging Research Team, Center for Epidemiology and Population Health Research, INSERM, Université Paul Sabatier, Toulouse, France (M.E.S.-M.); University of Exeter School of Medicine, Exeter, United Kingdom (C.B.); the Department of Neurology, Oregon Health and Sciences University, Portland (D.E.-L.); the Department of Psychiatry and Human Behavior and the Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine (D.L.S.), and Acadia Pharmaceuticals, San Diego (B.M., J.M.Y., S.S., E.P.F.) — both in California; the Department of Ps...
- Acadia Pharmaceuticals (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-07-22
- Volume
- 385
- Issue
- 4
- Pages
- 309-319
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3184254488
- Cited by
- 145
- References
- 31
- Citations by year
- 2026: 16 · 2025: 29 · 2024: 37 · 2023: 24 · 2022: 29 · 2021: 9
- FWCI
- 17.94
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Figshare (submittedVersion)
- Open Research Exeter (University of Exeter) (submittedVersion)
- Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (submittedVersion)
- Funders
- ACADIA Pharmaceuticals
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- pimavanserin, dementia-related psychosis, Alzheimer's disease, Parkinson's disease dementia, dementia with Lewy bodies, frontotemporal dementia, vascular dementia, relapse, delusions and hallucinations, antipsychotic withdrawal, adverse events, QT prolongation, drug discontinuation
- MeSH terms
- Aged, Aged, 80 and over, Dementia, Double-Blind Method, Female, Hallucinations, Humans, Male, Middle Aged, Parkinson Disease, Piperidines, Psychotic Disorders, Recurrence, Antipsychotic Agents, Urea, Proportional Hazards Models, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
